ストックスクリーナーアプリを入手
158.43
3.31%
5.07
アフターアワーズ：
158.43
前日終値:
$153.36
開ける：
$154.33
24時間の取引高:
136.53K
Relative Volume:
0.73
時価総額：
$6.35B
収益：
-
当期純損益:
$-77.61M
株価収益率:
-68.95
EPS:
-2.2979
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+3.66%
1か月 パフォーマンス:
+6.52%
6か月 パフォーマンス:
-5.32%
1年 パフォーマンス:
+154.55%
1日の値動き範囲:
$153.88
$159.26
1週間の範囲:
$151.35
$161.43
52週間の値動き範囲:
$60.00
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
158.43 | 6.15B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-26 | 開始されました | BofA Securities | Buy |
| 2026-01-06 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-02 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-11-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 開始されました | Mizuho | Neutral |
| 2023-12-14 | 開始されました | Maxim Group | Buy |
| 2023-07-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 開始されました | SVB Securities | Outperform |
| 2022-08-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-01 | 開始されました | The Benchmark Company | Buy |
すべてを表示
Belite Bio Inc Adr (BLTE) 最新ニュース
Price to sales forward of Belite Bio, Inc. ADR – FWB:D01 - TradingView
Belite Bio, Inc. ADR Revenue Breakdown – FWB:D01 - TradingView
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases - MarketBeat
Belite Bio stock price target maintained at $200 by H.C. Wainwright - Investing.com UK
Belite Bio stock price target maintained at $200 by H.C. Wainwright By Investing.com - Investing.com Australia
Belite Bio (BLTE) Leerink’s Global Healthcare Conference 2025 Summary - Quartr
Belite Bio presents additional Phase 3 trial data for tinlarebant By Investing.com - Investing.com South Africa
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 - The Manila Times
Belite Bio presents additional Phase 3 trial data for tinlarebant - Investing.com
Belite Bio (BLTE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BLTE - MarketBeat
Belite Bio, Inc. ADR (BLTE) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Responsive Playbooks and the BLTE Inflection - Stock Traders Daily
Belite Bio, Inc. ADR (BLTE) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Belite Bio, Inc. ADR (BLTE) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference - markets.businessinsider.com
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease - Yahoo Finance
Belite Bio at Piper Sandler ophthalmology day: drug data support filing - Investing.com India
Belite Bio Slumps As Market Turmoil Trumps Drug Hopes - TipRanks
How Phase 3 DRAGON Trial Data Showcases At Major Conferences At Belite Bio (BLTE) Has Changed Its Investment Story - Sahm
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - markets.businessinsider.com
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - The Manila Times
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - GlobeNewswire Inc.
Price to earnings forward of Belite Bio, Inc. ADR – FWB:D01 - TradingView
BLTE Stock Price, Quote & Chart - ChartMill
Belite Bio, Inc. ADR Actuals & Estimates (NASDAQ:BLTE) - TradingView
Understanding the Setup: (BLTE) and Scalable Risk - Stock Traders Daily
Belite Bio (BLTE) After Its FDA Filing, Does The Stock Still Look Undervalued - Sahm
H.C. Wainwright Keeps Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail
Top Executive Makes Major Move With Belite Bio Stock Sale - TipRanks
Belite Bio CMO Scholl sells over $1.45m in company shares - Investing.com Nigeria
Form 4 Belite Bio Inc ADR For: 22 June By Investing.com - Investing.com South Africa
Bioptima Ltd. tied to Belite Bio (BLTE) CMO sells 10,000 ADSs in open market - Stock Titan
Frontier tech research, news & data - MLQ.ai
Why Belite Bio (BLTE) Is Up 5.8% After Completing FDA NDA Submission For Tinlarebant - Sahm
BLTE News | BELITE BIO INCADR (NASDAQ:BLTE) - ChartMill
Dr. Hendrick Scholl sells 10,000 ADS as Form 144 filed (NASDAQ: BLTE) - Stock Titan
Belite Bio Soars After Key FDA Filing Milestone - TipRanks
Belite Bio CMO Scholl sells $1.4m shares from $137.61 to $145.02 - Investing.com India
Belite Bio (BLTE) CMO-affiliated entity sells 10,000 ADS, retains 32,946 - Stock Titan
BLTE (NASDAQ: BLTE) files Rule 144 notice to sell 10,000 ADS under vested RSUs - Stock Titan
Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Climb Bio (CLYM) and Intuitive Surgical (ISRG) - The Globe and Mail
BLTE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $200 - GuruFocus
Belite Bio (NASDAQ: BLTE) completes FDA NDA submission for tinlarebant in Stargardt disease - Stock Titan
The Technical Signals Behind (BLTE) That Institutions Follow - Stock Traders Daily
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 - The Manila Times
Belite Bio (BLTE) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Belite Bio Inc Adr (BLTE) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):